Treatment of Dyslipidaemias in Patients with Established Vascular Disease: A Revival of the Fibrates

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

1998 • 19,638 citations

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1994 • 8,631 citations

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

1998 • 8,603 citations

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

1998 • 7,971 citations

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

1996 • 7,450 citations

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

1995 • 7,378 citations

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

1996 • 6,350 citations

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1998 • 5,229 citations

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

1998 • 4,159 citations

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol

1999 • 3,464 citations

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

1994 • 3,408 citations

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

1994 • 2,993 citations

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1996 • 2,812 citations

Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B

1990 • 2,192 citations

Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies

1996 • 2,037 citations

Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris

1995 • 1,807 citations

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

1988 • 1,722 citations

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies

1996 • 1,658 citations

West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials

1996 • 1,584 citations

Fibrinogen as a Cardiovascular Risk Factor

1993 • 1,015 citations

Cholesterol and mortality. 30 years of follow-up from the Framingham study

1987 • 981 citations

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience)

1992 • 895 citations

Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels

1995 • 846 citations

Reduction of Mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by Combined Treatment with Clofibrate and Nicotinic Acid

1988 • 693 citations

Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

1994 • 648 citations

Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)

1998 • 639 citations

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1984 • 631 citations

Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes

1989 • 622 citations

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men.

1994 • 572 citations

Plasma Triglyceride Level and Mortality from Coronary Heart Disease

1993 • 425 citations

Angiographic Assessment of Effects of Bezafibrate on Progression of Coronary Artery Disease in Young Male Postinfarction Patients

1996 • 415 citations

Low-density lipoprotein subclass patterns and risk of myocardial infarction

1988 • 414 citations

The Role of Circulating Glucose and Triglyceride Concentrations and Their Interactions with Other “Risk Factors” as Determinants of Arterial Disease in Nine Diabetic Population Samples from the WHO Multinational Study

1983 • 409 citations

Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol

1997 • 394 citations

Comparison of Statins in Hypertriglyceridemia

1998 • 387 citations

The Münster Heart Study (PROCAM). Results of follow-up at 8 years.

1998 • 358 citations

HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.

1989 • 336 citations

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes.

1993 • 313 citations

Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS)

1994 • 309 citations

Statin—Fibrate Combination Therapy

2001 • 273 citations

Relation of High TG–Low HDL Cholesterol and LDL Cholesterol to the Incidence of Ischemic Heart Disease

1997 • 262 citations

PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

2004 • 247 citations

Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk

1994 • 233 citations

Postprandial lipemia, fenofibrate and coronary artery disease

1990 • 230 citations

Atherogenicity of Triglyceride-Rich Lipoproteins

1998 • 229 citations

Lp(a) lipoprotein in cardiovascular disease

1994 • 220 citations

Acute Effects of Insulin in the Control of VLDL Production in Humans: Implications for the insulin-resistant state

1996 • 220 citations

The Münster Heart Study (PROCAM)

1997 • 207 citations

The insulin resistance syndrome in smokers is related to smoking habits.

1994 • 190 citations

Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.

1998 • 179 citations

The atherogenic lipoprotein phenotype and vascular endothelial dysfunction

1998 • 162 citations

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1995 • 161 citations

Combination Drug Therapy for Familial Combined Hyperlipidemia

1988 • 127 citations

Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

1993 • 120 citations

Differences in Lipoprotein Subfraction Composition and Distribution Between Type I Diabetic Men and Control Subjects

1990 • 101 citations

Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia

1999 • 83 citations

Effects of Gemfibrozil and Other Fibric Acid Derivatives on Blood Lipids and Lipoproteins

1991 • 79 citations

Triglycerides are more important in atherosclerosis than epidemiology has suggested

1998 • 76 citations

Dyslipidemia in diabetes mellitus

1996 • 71 citations

The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, Type 2 (non-insulin-dependent) diabetic patients

1991 • 70 citations

Epidemiological aspects of high density lipoprotein cholesterol1Presented at the 68th meeting of the European Atherosclerosis Society, Brugge, 8–10 May, 1997.1

1998 • 65 citations

Gemfibrozil Reduces Plasma Prothrombin Fragment F1+2 Concentration, a Marker of Coagulability, in Patients with Coronary Heart Disease

1992 • 58 citations

Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia

1993 • 58 citations

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.

1995 • 56 citations

Statin + fibrate combination therapy

1999 • 55 citations

Effects of One Year of Treatment with Pravastatin, an HMG‐CoA Reductase Inhibitor, on Lipoprotein a

1993 • 52 citations

Family similarities in the age at coronary death in familial hypercholesterolaemia.

1977 • 50 citations

Effects of ciprofibrate on LDL metabolism in man

1994 • 47 citations

Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.

1998 • 46 citations

Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

1992 • 44 citations

Fibrinogen and Its Relations to Subclinical Extracoronary and Coronary Atherosclerosis in Hypercholesterolemic Men

1997 • 40 citations

Lovastatin Alters Blood Rheology in Primary Hyperlipoproteinemia: Dependence on Lipoprotein(a)?

1992 • 37 citations

Lipids and stroke: neglect of a useful preventive measure?

1998 • 31 citations

Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects

1990 • 30 citations

Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects.

1996 • 27 citations

Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia

1996 • 22 citations

Effects of Combined Bezafibrate‐Simvastatin Appraised in Healthy Subjects

1992 • 19 citations

Recent Progress in the Clinical Aspects of Fibrinogen

1995 • 16 citations

Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions

1990 • 15 citations

Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients

1995 • 12 citations

Correspondence

1999 • 11 citations

Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia

1996 • 10 citations

Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.

1997 • 10 citations

Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia

1996 • 10 citations

Biological Importance of Low-Density-Lipoprotein Subfractions

1994 • 8 citations

Fibrinogen as a cardiovascular risk factor.

1997 • 8 citations

[Gemfibrozil reduces elevated lipoprotein (a) levels in hypercholesterolemic patients].

1997 • 4 citations

Beneficial effects of statins

1996 • 1 citations

Deleted Work

1955 • 0 citations

Cited By (0)

Loading...